Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sucampo Pharmaceuticals, a specialty biopharmaceutical company, has appointed Kathryn Santis as its new vice president of investor relations and corporate communications.
Subscribe to our email newsletter
For the past 11 years, Ms Santis served as director of investor relations and corporate communications at Human Genome Sciences.
Ms Santis holds an MBA in marketing management from Pace University’s Lubin Graduate School of Business, in White Plains, New York, and a BA in english literature from Molloy College, in Rockville Centre, New York.
Ryuji Ueno, chairman and CEO of Sucampo, said: “I am very pleased to welcome Kate to Sucampo. We look forward to utilizing her extensive expertise in the life sciences industry as we shape our investor relations and corporate communications’s program.”